ValuEngine cut shares of Selecta Biosciences (NASDAQ:SELB) from a sell rating to a strong sell rating in a research note published on Friday morning.
Other equities analysts also recently issued reports about the company. Zacks Investment Research downgraded Selecta Biosciences from a buy rating to a hold rating in a research report on Wednesday, January 10th. Canaccord Genuity lifted their target price on Selecta Biosciences from $25.00 to $30.00 and gave the company a buy rating in a research report on Thursday, October 12th. Finally, UBS Group downgraded Selecta Biosciences from a buy rating to a neutral rating in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $23.50.
Shares of Selecta Biosciences (NASDAQ SELB) traded down $0.25 during trading hours on Friday, hitting $8.76. The company had a trading volume of 220,022 shares, compared to its average volume of 281,479. The firm has a market cap of $201.25, a P/E ratio of -2.83 and a beta of -5.56. The company has a quick ratio of 9.48, a current ratio of 9.48 and a debt-to-equity ratio of 0.32. Selecta Biosciences has a 1 year low of $8.40 and a 1 year high of $24.02.
Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Tuesday, November 7th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.22. Selecta Biosciences had a negative return on equity of 100.06% and a negative net margin of 1,918.59%. sell-side analysts expect that Selecta Biosciences will post -2.25 EPS for the current year.
In other news, insider Earl Sands bought 7,500 shares of the company’s stock in a transaction on Friday, November 17th. The stock was bought at an average cost of $10.26 per share, with a total value of $76,950.00. Following the transaction, the insider now directly owns 7,500 shares in the company, valued at approximately $76,950. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy C. Barabe acquired 5,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was bought at an average price of $9.37 per share, with a total value of $46,850.00. Following the purchase, the director now directly owns 4,992 shares in the company, valued at approximately $46,775.04. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 90,098 shares of company stock valued at $843,933. 41.90% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors boosted its stake in shares of Selecta Biosciences by 224.5% in the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock valued at $131,000 after buying an additional 4,561 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Selecta Biosciences by 1.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 365,138 shares of the company’s stock valued at $7,131,000 after buying an additional 6,292 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Selecta Biosciences by 184.0% in the 2nd quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock valued at $248,000 after buying an additional 8,099 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Selecta Biosciences by 26.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 41,020 shares of the company’s stock valued at $748,000 after buying an additional 8,620 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Selecta Biosciences by 50.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 29,600 shares of the company’s stock valued at $541,000 after buying an additional 9,900 shares during the period. Institutional investors and hedge funds own 54.81% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/03/selecta-biosciences-selb-downgraded-to-strong-sell-at-valuengine.html.
About Selecta Biosciences
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.